Central Nervous System Disorder Articles & Analysis
24 news found
One of the reasons for the lack of effective treatments is due to suboptimal penetration of the blood-brain barrier for potential drug candidates into the central nervous system. This results in both poor distribution and efficacy. ...
This is not an insignificant achievement. “Central nervous system disorders are a scourge because they are challenging to treat by their very nature. ...
Kurve Therapeutics has developed a cutting-edge approach to treating central nervous system (CNS) disorders. These debilitating disorders afflict millions of people worldwide, yet they lack effective disease-modifying treatments. ...
Kurve Therapeutics has succeeded in bypassing the blood-brain barrier with their patented Controlled Particle Dispersion® (CPD) technology, creating new hope in the treatment of central nervous system disorders. The company urges CNS researchers to reach out for collaboration in providing care for this very large global ...
("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. ...
PARIS, FRANCE, March 3, 2022, PRNewswire – Qynapse SAS, a medical technology company commercializing an FDA approved/CE cleared AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to announce that a symposium oral presentation and a poster presentation will be delivered at ...
ByQynapse
By revealing the connections between the gut and the brain, the Kallyope platform has been leveraged to generate novel programs spanning several relevant therapeutic areas, including metabolism, immunology and inflammation, and central nervous system disorders. A key element of the Kallyope strategy is to target gut and gut-brain ...
BOSTON, MA, February 14, 2022, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to present 2 posters at the annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum ...
ByQynapse
BOSTON, MA, November 22, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an artificial intelligence (AI)-powered neuroimaging software platform for central nervous system (CNS) disorders, will unveil its new brand and latest AI developments as a key exhibitor in the AI Showcase at the 107th ...
ByQynapse
Food and Drug Administration (FDA) for its groundbreaking MoveAgain Brain Computer Interface (BCI) system. There are an estimated 5.35 million1 people in the United States who suffer from paralysis due to central nervous system disorders, autoimmune diseases, and spinal cord injuries. Blackrock’s MoveAgain ...
BOSTON, MA, November 4, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to sponsor the 14th Clinical Trials on Alzheimer’s Disease conference (CTAD) to be held from November 9-12, 2021, ...
ByQynapse
Axial Therapeutics Inc., a clinical-stage biopharmaceutical company focused on leveraging the gut-brain axis for the discovery and development of small molecule therapeutics with an initial focus on autism spectrum disorder (ASD) and Parkinson’s disease (PD), today announced the appointment of A. ...
Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today the appointment of Bryan Phillips as Senior Vice President, General Counsel, Chief Compliance Officer and ...
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a fireside chat at the virtual H.C. ...
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a keynote presentation at the ACCESS CHINA Forum @JPM WEEK 2021 Conference on Tuesday, ...
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a fireside chat at the 2020 RBC Capital Markets Healthcare Private Company Conference on ...
Axial R&D Leader to Chair Day-long Session on Clinical Trials for ASD and New Therapeutics Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that A. ...
“These key pharmacological benefits open the door to a host of other peripheral and central nervous system diseases and disorders as well.” KLS-13019 leads Kannalife’s intellectual property portfolio of novel monotherapeutic molecules (“KLS Family”), which have been proven capable of acting as ...
” About Hansoh Pharma Hansoh Pharma (3692:HK) is a leading biopharmaceutical company in China committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders. Hansoh Pharma has over 9,000 dedicated employees in China and the United States. Founded in 1995, Hansoh has fully integrated research and development, ...
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will present a company overview at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2019 at 1:10 PM ET in New York, NY. About Axial Therapeutics ...